Longeveron (LGVN) has shared an update.
Longeveron Inc., a biotech firm, has engaged in financial maneuvers to strengthen its position in the market. By striking inducement letter agreements, the company prompted holders of its existing warrants to purchase shares at a set price, securing approximately $6.2 million before expenses. This influx of cash is earmarked for the development of Lomecel-B™ for various diseases, including Alzheimer’s. Additionally, the company appeased NASDAQ’s concerns by meeting the minimum bid price requirement, thus averting the risk of delisting and ensuring continued compliance with stock market regulations.
See more data about LGVN stock on TipRanks’ Stock Analysis page.
